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INTRODUCTION

The cholinergic and dopaminergic systems are essential for cognition and motor
function. Studies examining the roles of these neurotransmitter systems have shown that
they interact in a complex fashion (for review see Levin et al., 1990). Several sites of
dopamine (DA)-acetylcholine (ACh) interaction already have been demonstrated,
including the striatum (STR) and the septum.
Within the rat STR, DA fibers originating in the substantia nigra (SN) and ventral
tegmental area (VTA) (Fallon and Moore, 1978) form close appositions with large,
dendritic spine-free cells thought to represent cholinergic interneurons (Heimer et al.,
1985; Lehmann and Langer, 1983). Electron microscopic (EM) analysis of double-labeled
striatal sections revealed that tyrosine hydroxylase (TH)-immunoreactive (IR) terminals
contact choline acetyltransferase (ChAT)-positive terminals of these interneurons (Chang
1988; Kubota et al., 1987). Furthermore, D1-like and D2-like receptor subtypes (Ariano
et al., 1989; Camps et al., 1990; Contreras et al., 1987; Gehlert and Wamsley, 1985;
Guela and Slevin, 1989; Mansour et al., 1990; Richfield et al., 1989), and their respective
mRNA (Mansour et al., 1990; Meador-Woodruff et al., 1990; Mengod et al., 1991;
Weiner et al., 1990), are prevalent in the STR. The D1-like receptor is positively coupled
to adenylate cyclase and the D2-like receptor (henceforth these receptors are referred to
as D1 and D2, respectively) is negatively coupled with the enzyme (Stoof and Kebabian,
1984).
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In vivo data measuring ACh concentration and in vitro data measuring ACh release

indicate that DA exerts an inhibitory effect on the striatal cholinergic cells, a phen9menon
thought to be mediated by D2 receptors (Sherman et al., 1978; Scatton, 1982a; 1982b;
Stoof and Kebabian, 1982; Fage et al., 1984). Results concerning the involvement of DI
receptors are variable.
Experiments utilizing acute treatments with DI-selective agonists and antagonists
do not support a DI-mediated inhibition of striatal cholinergic function. According to
Scatton (1982b) and Stoof and Kebabian (1982), a pharmacological challenge with the DI
receptor agonist, SKF 38393 has no effect on striatal ACh concentration in vivo or ACh
release from striatal slices. Other agents which increase cAMP content likewise do not
change ACh release (Stoof and Kebabian, 1982). Contrasting data from Gorell et al.
shows that application of either SKF 38393 or the D 1 receptor antagonist, SCH 23390
causes a dose-dependent increase in ACh release that is not blocked by the D2 receptor
antagonist, sulpiride. According to Gorell and associates, this indicates that the ACh
release is mediated by receptors other than DI or D2 (Gorell and Czarnecki, 1986; Gorell
et al., 1986). Recent work has demonstrated that D 1 receptors stimulate and D2 receptors
inhibit striatal ACh output as measured by in vivo microdialysis (Damsma et al., 1991;
DeBoer and Abercrombie, 1992). Furthermore, results also "suggest that an increased
ACh release is mediated by a preferential stimulation of Dl receptors" (Imperato et al.,
1992).
Published data concerning chronic DAergic drug treatment also are inconclusive.
Rupniak et al. (1986) and Jenner and Marsden (1987) reported that 12 months'
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administration of the atypical neuroleptic, clozapine to rats increases binding (Bmax) of
[3H]piflutixol to striatal Dl receptors, but does not influence binding of [3H]spiperone
to striatal D2 sites. A concomitant increase in striatal ACh concentration also occurs,
while striatal ChAT activity remains unchanged from control. A similar phenomenon
occurs with chronic haloperidol (a D2 antagonist), which selectively increases striatal
[3H]spiperone binding and ACh levels without affecting ChAT. Long-term sulpiride that
does not induce D2 receptor upregulation in STR, also does not affect striatal ACh
concentration or ChAT activity (Jenner and Marsden, 1987; Rupniak et al., 1986).
The septum, which contains Dl and D2 receptors (Camps et al., 1990; Contreras
et al., 1987; Gehlert and Wamsley, 1985; Mansour et al., 1990; Richfield et al., 1989;
Weiner et al., 1990), is another site of DA-ACh interaction. DA inputs originate entirely
in the VT A and terminate primarily in the septum (Beckstead et al., 1979; Fallon and
Moore, 1978; Onteniente et al., 1984; Palkovits and Brownstein, 1988; Robinson et al.,
1979). In the septum, DA projections interact with ACh neurons whose cell bodies are
located in the medial septum (MS) and whose axons terminate in the hippocampus (Bigl
et al., 1982; Koliatsos et al., 1988; Saper, 1984; Woolf and Butcher, 1985; Woolf et al.,
1984).
The DA axons appear to exert a tonic inhibitory influence on the
septohippocampal cholinergic neurons. lntraseptal haloperidol selectively increases ACh
turnover in hippocampus without altering ACh concentration (Robinson et al., 1979).
Haloperidol also produces a long-lasting increase in hippocampal sodium-dependent highaffinity choline uptake (HAChU; Durkin et al., 1986).

Local injection of 6-
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hydroxydopamine (6-0HDA) into septum or VTA (area AlO) likewise augments
hippocampal ACh turnover without affecting ACh levels (Robinson et al., 1979).
Intraperitoneal sulpiride increases HAChU and ACh release (Gilad et al., 1986), while
low-dose apomorphine (s.c.), a nonspecific DA receptor agonist, reduces ACh turnover
(Robinson et al., 1979) in hippocampus.
Evidence suggests that DA projections from the VT A and SN interact with
cortically-projecting cholinergic cells in the nonseptal basal forebrain. This thesis focuses
on the infracommissural extension of the dorsal globus pallidus (GP) known as the ventral
pallidum (VP), and the caudal extension of the VP known as the sublenticular substantia
innominata (SI; Heimer and Wilson, 1975). Data indicate that the VP/SI: 1.) receives
inputs from dopaminergic nuclei of the brain stem (Beckstead et al., 1979; Haring and
Wang, 1986; Martinez-Murillo et al., 1988; Russchen et al., 1985; Semba et al., 1988;
Voorn et al., 1986); 2.) contains DA and its metabolites (Guela and Slevin 1989; Napier
and Potter, 1989);

3.) is sensitive to local injections of DA and to systemically-

administered DA agonists (Maslowski and Napier, 1989, 1991; Napier et al., 1991a;
Napier and Breese, 1986; Napier and Maslowski, 1988; Napier and Potter, 1989); and
4.) contains Dl and D2 receptors (Beckstead et al., 1988; Contreras et al., 1987; Gehlert
and Wamsley, 1985; Guela and Slevin, 1989; Napier et al., 1991b). Preliminary studies
with tissue homogenates in our laboratory confirmed the presence of these DAergic
receptors in VP/SI and demonstrated that DA uptake sites exist in this region (Napier et
al., 1991b).

The VP/SI also contains large, cortically-projecting cholinergic cells

(Armstrong et al., 1983; Dinopoulos et al., 1988; Saper 1984) and anatomical studies
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suggest that catecholaminergic terminals contact distal dendrites and somata of VP/SI
cholinergic neurons (Martinez-Murillo et al, 1988; Zaborszky et al., in press; Zaborszky
et al., 1991; Zaborszky, 1989). That a 6-OHDA-induced lesion of the SN or medial
forebrain bundle (mfb) decreases DA concentration in the VP/SI and STR (Guela and
Slevin, 1989; Napier and Potter, 1989) and reduces ChAT activity in the nucleus of the
vertical limb of the diagonal band (VDB) and nucleus of the horizontal limb of the
diagonal band (HDB) (Zaborszky et al., in press; Zaborszky 1989) suggests that basal
forebrain cholinergic neurons are sensitive to Daergic influence.
Thus, the research presented here explored the possibility that terminal regions of
VP/SI cholinergic cells react to manipulations of the DA system. Rats were treated for
21 days with DI- or D2-receptor-specific antagonists. Radioligand binding of [3H]SCH
23390 and [3H]spiperone to VP/SI tissue homogenates obtained from these animals was
employed to indicate whether DI and/or D2 receptors, respectively, adapted to this
pharmacological challenge. ChA T activity in cortex and amygdala served as a marker for
changes in VP/SI cholinergic terminal function (Kuhar, 1976; Russchen et al., 1985;
Watson et al., 1985). For comparison purposes these parameters also were examined in
the STR and septohippocampal system, where DA-ACh interactions already have been
established. The morphologic and electrophysiologic similarity of the GP to the VP
(Heimer and Wilson, 1975; Napier et al., 1991a) prompted us to record receptor changes
in the GP as well.

LITERATURE REVIEW

Recent evidence indicates that the nucleus basalis of Meynert (NB) of the basal
forebrain is an important part of the motor and limbic systems in primates (Heimer and
Wilson, 1975; Mitchell et al., 1987; Richardson and DeLong, 1988). As such, the NB
participates in a multisynaptic pathway which channels neural information from core
limbic structures to modality-specific cortical areas (Mesulam et al., 1986). Serving as
a point of convergence, the basal forebrain has substantial influence in the pathologies of
many neurological disorders (Homykiewicz et al., 1984; Mesulam et al., 1983).
Degeneration of the NB, for example, contributes to the cognitive deficits of Alzheimer's
Disease (Durkin, 1989; Kordower et al., 1989; Mufson and Kordower, 1989; Richardson
and DeLong, 1988; Salamone, 1986). Whether loss of neurotransmitter systems that
project to NB contributes to the dementia of Alzheimer's or other neurological diseases
is unknown.

To better deduce the role of the NB, it is necessary to understand its

anatomical location and communicative framework.
The NB is included in a collection of magnocellular cholinergic neurons spanning
the entire human basal forebrain. The simian analogue of this nucleus consists of the
cholinergic cells extending anteriorly from the level of the olfactory tubercle to the ansa
peduncularis, posteriorly (Mesulam et al., 1983). The NB equivalent in rodent is not so
easily defined.
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Schwaber et al. ( 1987) used a digital microscopy system to construct a threedimensional model of the distribution of cholinergic cells in rat basal fore brain .. From a
top view, the rostral cholinergic projection neurons lie along the midline within the MS
and VDB. Slightly posterior to VDB, in the HDB, the distribution sweeps caudolaterally
to the crossing of the anterior commissure (xac).

As it progresses caudally, the

cholinergic cell column spreads laterally into the magnocellular preoptic area (MPO), the
VP, and SL At the most posterior levels, the column narrows to "sheets of cells" along
the lateral border of the internal capsule (ic) (Schwaber et al., 1987).
In attempting to determine the rat homologue of the primate NB, researchers
studied forebrain sections ranging from the xac and the relevant nuclei at that level (i.e.,
HDB, MPO, VP), to the most posterior sections which included the SI, ventromedial
globus pallidus (vmGP) and the peri-capsular cholinergic cells (actually labeled "basal
nucleus of Meynert" in the atlas of Paxinos and Watson, [1986]). With some variation,
the cortically-projecting, cholinergic cell population in this entire area often is referred
to as the magnocellular basal nucleus (MBN). Unfortunately, much confusion in basal
forebrain nomenclature has arisen from research to identify the rodent equivalent of the
primate NB. The forebrain cholinergic column fails to coincide with any one structure.
Instead, it is included in several of the cytoarchitecturally distinct nuclei within each brain
region through which it passes (Armstrong et al., 1983; Luiten et al., 1987; Saper, 1984;
Schwaber et al., 1987; Zaborszky, submitted; Zahm, 1989). Furthermore, "... authors have
used different terms for the same [forebrain] structure, as well as the same term for
completely different structures" (Butcher and Semba, 1989). Because the anatomical
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connections (Bigl et al., 1982; Luiten et al., 1987; Saper, 1984; Woolf et al., 1984) and
functional significance (Heimer and Alheid, 1991) of the anterior vs posterior MBN have
been reported to differ, it is important to consider the MBN coordinates given when
interpreting published data in this field.

Efferents

Anatomical evidence agrees that the primary efferents of the primate NB (Kohler
et al., 1984; Mesulam et al., 1983; Mesulam et al., 1986) and the rodent MBN
(Eckenstein et al., 1988; Houser et al., 1985; Luiten et al., 1987; Saper, 1984; Woolf and
Butcher, 1985; Woolf et al., 1984) project ipsilaterally to the entire cortical mantle.
Moderately-large, morphologically-similar, ChAT-positive cell bodies of the NB or MBN
(Armstrong et al., 1983; Dinopoulos et al., 1988; Mesulam et al., 1983; Saper 1984) are
the "single major source of cholinergic innervation" to the cortex (Mesulam, 1983).
Studies have shown that 80-90% of all cortically-projecting axons arising from the basal
nuclei are cholinergic, the highest percentage originating in the most caudal regions
(Luiten et al., 1987; Mesulam et al., 1983; Rye et al, 1984). Biochemical data confirm
these conclusions. MBN lesions in the VP/SI and in vmGP/ic produce significant
decreases in cortical ChAT activity (30-70%) (Fibiger et al, 1988; Saper, 1984; SantosBenito et al., 1988; Watson et al., 1985; Watson et al., 1985; Wenk et al., 1980) and
reduce the Bmax (45%) for HAChU carriers (Watson et al.,1985).
The organization of MBN axons is still unknown.

Experiments in rat brain

utilizing ChAT and/or acetylcholinesterase (AChE) histochemistry in conjunction with the
anterograde tracer phaseolus vulgaris leucoagglutinin (PHA-L) (Luiten et al., 1987), or
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with retrograde fluorescent label horseradish peroxidase (HRP) (Bigl et al., 1982;
Koliatsos et al., 1988; Saper, 1984; Woolf and Butcher, 1985; Woolf et al., 1984), have
indicated several trends. First, anterior MBN, but not posterior MBN. sends a moderate
projection to limbic structures in mesocortex (i.e., infralimbic, prelimbic, anterior
cingulate, retrosplenial, orbitofrontal, agranular insular, and perirhinal corticies) and
allocortex (i.e., olfactory bulb, anterior olfactory nucleus, olfactory tubercle, lateral
piriform, and entorhinal corticies). Second, the most caudal aspect of anterior MBN and
the intermediate MBN innervate anterior neocortex, whereas only the posterior MBN
substantially innervates posterior neocortex. The exception to this is the occipital cortex,
which receives fibers from the most anterior MBN. All areas of the MBN still maintain
their predominant output to frontal-parietal cortices in terms of the quantity of fibers.
Also, all subdivisions of MBN send numerous axons to the amygdala.

Third, there

appears to be a loose dorsomedial-ventrolateral organization. Anterior MBN, the most
medial section, projects to dorsomedial cortex, and posterior MBN, the most lateral
section, to ventrolateral cortex. Similar patterns of innervation were observed in primates
(Koliatsos et al., 1988; Mesulam et al., 1983, 1986). The heterogeneity of cholinergic
markers across the cortical surface (Lehmann et al., 1984, Mesulam et al., 1986), or the
differential branching between the neurons innervating the anterior and posterior cortex
(McKinney et al., 1983; Price and Stern, 1983), might partially explain discrepancies in
the literature.
The MBN traditionally has referred to the cholinergic neurons located in the
ventral forebrain, as described previously. However, the nuclei containing the MBN also
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contain non-cholinergic cells.

These may contribute to the neurological pathologies

involving the basal forebrain, either by their own projections or by their interaction with
the cholinergic neurons. Anatomical evidence demonstrated that the cholinergic neurons
represent only a small percentage of the total cell groups of the basal forebrain nuclei
(e.g., Saper, 1984).

Different neuron subpopulations also have been identified

electrophysiologically (Aston-Jones, 1985; Griffith, 1988; Griffith and Matthews, 1986).
Cholinergic and GABAergic projection neurons are intermingled throughout the basal
forebrain and exhibit remarkable structural similarity (Fallon and Moore, 1978; Kohler
et al., 1984; Zaborszky et al., 1986). Axons of both cell types follow similar trajectories
to their targets, including the cortex (Woolf and Butcher, 1985; Woolf et al., 1986).
Non-cortical efferents from the basal forebrain region between the xac and vmGP
have been demonstrated, although in many cases the neurotransmitters have not been
identified. These efferents reach the reticular nucleus of the thalamus (Heimer et al.,
1985; Levey et al., 1987) the mediodorsal thalamic nucleus (Heimer et al., 1982, 1985;
Heimer and Wilson, 1975; Young et al., 1984; Zahm et al., 1987), the ventral striatum
[vSTR (Haber et al., 1985; Heimer et al., 1985)], the entopeduncular nucleus (GPep;
Heimer et al., 1985), the mesencephalic locomotor region (Mogenson and Wu, 1986), the
substantia nigra (Haber et al., 1985; Woolf et al., 1984; Zahm, 1989), and the ventral
tegmentum (Haber et al., 1985; Zahm, 1989).

As indicated by its location and

connections, the basal forebrain may integrate limbic and motor systems.

Functional Significance of Efferent Projections
The ventral striatopallidal system, in parallel with the dorsal striatopallidal system,
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work together for the planning and initiation of movements (Heimer et al., 1982).
Behavioral studies in primates have shown that the neurons in the SI/NB exhibit changes
in activity preceding reinforced (rewarded) movements during a task (Mitchell et al.,
1987; Richardson and DeLong, 1988). Therefore, a change in ACh released to the cortex
is expected during reinforcement.
ACh has been suggested to contribute to many functions in the cortex, including
state of arousal (Bradley and Elkes, 1957; Longo, 1955; Phillis, 1968), learning (Mandel
et al., 1974), and memory (Davis et al., 1978). ffrench-Mullen et al. (1983) discovered
that pyramidal neurons of rat prepyriform cortex increase firing rates in response to
application of ACh.

In cells which do not respond, ACh potentiates responses to

glutamate and aspartate. Both excitation and potentiation by ACh are blocked by the
muscarinic receptor antagonist, atropine but not by the nicotinic receptor antagonist,
curare (ffrench-Mullen et al., 1983). Richardson and DeLong (1988) demonstrated that
direct application of ACh onto cortical and hippocampal neurons causes a prolonged
decrease in a ca++ -activated potassium current with a consequent decrease in afterhyperpolarization. This alteration of the cell's responsiveness can last more than an hour
in certain cortices (Richardson and DeLong, 1988).

In a study combining

electrophysiological and behavioral techniques in monkeys, Aou et al. (1983) observed
that 90% of ACh-sensitive cells in orbitofrontal cortex change activity during a bar-press
feeding task.

Of these neurons, 67% respond to more than one phase of the task.

Atropine antagonizes the excitatory response to ACh in this paradigm, similar to the result
in ffrench-Mullen's experiment.
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Pirch and associates have demonstrated in rats that the increase in VP/SI activity
preceding reinforcement is essential for the normal development of cue-elicited slow
potentials (Rigdon and Pirch, 1984; 1986). Slow potentials are recorded from rat frontal
cortex in response to a reinforced stimulus. Pirch observed that these specific waveforms
are suppressed by VP/SI lesioning, by VP/SI microinjection of procaine or GABA (to
depress neuronal activity), or by cortical muscarinic receptor blockade (Pirch et al., 1986;
Rigdon and Pirch, 1984; 1986). These results provide evidence that cortical responses
are dependent upon cholinergic innervation from the MBN. They also demonstrate the
possibility that the GABAergic cells intermingled with MBN may influence cortical
function via modulation of the cholinergic efferents, and by a direct GABAergic
projection to cortex.
ACh release from VP/SI terminals preceding reinforced movements may contribute
to state of arousal or learning and memory, by producing increased responsiveness in
cortical neurons (Richardson and DeLong, 1988). This hypothesis is supported by several
researchers who reported that lesions of VP/SI cholinergic neurons, which decrease
cortical ChAT by 30-40%, cause learning and memory deficits in rats (Altman et al.,
1985; Chrobak et al., 1987; 1988; Friedman et al., 1983; Murray and Fibiger, 1985; Ueki
and Miyoshi, 1989).

Afferents

While the efferents of the basal forebrain cholinergic system have long been
investigated, information concerning the afferents to the nuclei containing the MBN is just
beginning to accumulate.

The complexity of this region indicates that interactions
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between its various cell components play an important role in regulating cholinergic
transmission in the cortex.

Since removal of synaptic input causes up-regulation of

receptors, disruption of cellular metabolism or even transsynaptic degeneration, knowledge
of the afferent connections of the VP/Sl/vmGP (rat) and SI/NB (primate) might unfold
some pathophysiological mechanisms of Alzheimer's disease, Parkinson's disease, and
other forms of dementia.
Inputs to the SI/NB are predominantly ipsilateral and originate from a variety of
sources (Irle and Markowitsch, 1986; Semba et al., 1988). Studies in primates using HRP
or PHA-L with AChE staining, or with tritiated amino acids, revealed a cortical
innervation of SI/NB exclusively from limbic or paralimbic areas. Only the orbitofrontal,
medial temporal, prepyriform, periamygdaloid, entorhinal, and anterior insular corticies
are connected reciprocally with the SI/NB. The rest of the neocortex, i.e., posterior
parietal, peristriate, lateral temporal and posterior insular, does not project to SI/NB (Irle
and Markowitsch, 1986; Mesulam and Mufson, 1984; Russchen et al., 1985). Therefore,
SI/NB receives information from the sensory modalities (except olfaction) only after
extensive cortical processing.
The vSTR, nucleus accumbens (NA), and olfactory tubercle (OT) send substantial
fibers to VP/SI (Bolam et al., 1986; Grove et al., 1986; Haber and Nauta, 1983; Heimer
et al., 1985; Heimer and Wilson, 1975; Russchen et al., 1985; Zaborszky et al., 1982;
1986).

This projection is thought to be analogous to that from dorsal STR to GP

(Armstrong et al., 1983; Heimer et al., 1982; 1985).

PHA-L filled axons from vSTR

seem to selectively contact cell somata of ChAT-positive or AChE-positive VP/SI neurons
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(Bolam et al., 1986), while non-cholinergic VP/SI cells are enmeshed by striatopallidal
"woolly fibers", a common characteristic of striatopallidal connections (Grove et aL, 1986;
Haber and Nauta, 1983).

Zahm and Heimer (1988) noted that medial VP is

topographically related to medial vSTR in terms of neurotensin-immunoreactivity (NT-IR
[a characteristic of neuronal fibers]).

Because NT-IR also is associated with the

(medially) adjacent bed nucleus of the stria terminalis (BNST), they suggested that this
medial ventrostriatopallidal pathway is included in a larger basal forebrain circuit involved
with emotional behavior and memory.

This hypothetical system coincides with the

"extended amygdala" (Heimer et al., 1985), consisting of "a continuum formed by the
centromedian amygdala, sublenticular SI, and BNST with direct output channels to
visceromotor and somatomotor centers in the brainstem and spinal cord and reciprocal
relations with the hypothalamus." (Heimer and Alheid, 1991)
Immunohistochemical evidence demonstrates that GABAergic fibers of the NA
project to VP/SI (Heimer et al., 1985) and neurochemical studies have shown that
electrical stimulation of NA decreases cortical ACh turnover (Wood and McQuade, 1986).
Many researchers have confirmed: the high concentration of glutamic acid decarboxylase
(GAD) in the VP/SI region (Ingham et al., 1988), the dense GAD-immunoreactive
terminals surrounding VP/SI cells (Ingham et al., 1988; Zaborszky et al., 1986), and that
GABA axon terminals form synapses with VP/SI cholinergic neurons (Chang, 1989;
Ingham et al., 1986; Ingham et al., 1988; Zaborszky et al., 1986). Unilateral injection of
the GABA receptor agonist, muscimol into the VP decreases ACh output from the
ipsilateral frontoparietal cortex. Interestingly, both the GABA receptor antagonist,
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picrotoxin and the catecholamine releasor, amphetamine antagonize this effect (Casamenti
et al., 1986). Microinfusion of muscimol into the SI decreases cortical HAChU (Wenk,
1984). Direct injections and parenteral muscimol decrease cortical ACh turnover, an
effect suppressed by picrotoxin.

Picrotoxin administered alone does not produce an

effect, indicating that the GABAergic transmission influencing MBN is not tonicallyactive (Wood, 1986; Wood and McQuade, 1986; Wood and Richard, 1982).
Other important afferents to rat VP/SI or primate SI/NB originate in the amygdala.
Heaviest projections are from the basal amygdala nuclei, especially the basolateral
nucleus, and from the central nucleus. EM studies have shown that amygdalofugal fibers,
likely glutamatergic, synapse on the basal forebrain ChAT-positive cells. MBN also
returns a dense projection to the amygdala (Irle and Markowitsch, 1986; Russchen et al.,
1985; Semba et al., 1988; Zaborszky and Cullinan, 1989; Zaborszky et al., 1984). The
amygdala is connected to the olfactory system, the sensory association areas of the
temporal and insular corticies, temporal pole, orbitofrontal cortex, perirhinal cortex,
entorhinal cortex, and the subiculum.

Furthermore, nuclei of the hypothalamus and

brainstem provide the amygdala with autonomic and visceral information.

The

predominance of the amygdala projection to MBN demonstrates that polysensory and
limbic convergence centers channel neural information to the basal forebrain (Mesulam
and Mufson, 1984; Russchen et al., 1985).
The diencephalon also innervates the basal forebrain. Inputs include axons from
the ventromedial hypothalamus and the lateral hypothalamus (Haring and Wang, 1986;
Irle and Markowitsch, 1986; Russchen et al., 1985) which establish synaptic contact with
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cholinergic projection cells of the VP/SI (Zaborszky and Cullinan, 1989). The area also
is innervated by the thalamus, including the centromedian and parafascicular nuclei, and
by the subthalamus--zona incerta (Haring and Wang, 1986; Irle and Markowitsch, 1986;
Russchen et al., 1985; Zaborszky and Cullinan, 1989).
A variety of structures found in the brainstem project to VP/SI or SI/NB. These
are: the dorsal raphe, the periaqueductal gray, the pedunculopontine nucleus, the
parabrachial nuclei, the pontine and medullary reticular formation, the retrorubral area,
the solitary nucleus and the locus coeruleus [LC, (Haring and Wang, 1986; Irle and
Markowitsch, 1986; Russchen et al., 1985; Semba et al., 1988)].
Most relevant to this thesis is the evidence for a rnidbrain DA projection to the
VP/SI and vmGP/ic.

DA neurons of the substantia nigra pars compacta (SNc) are

continuous with the DA cells located in the ventrolateral tegmental region near the caudal
pole of the SN, and with those located dorsomedially in the VTA (Beckstead et al., 1988;
Deutch et al., 1988; Fallon and Moore, 1978). HRP injections into VP/SI or vmGP/ic
retrogradely label cells in the SNc and VTA, although sparsely (Haring and Wang, 1986;
Russchen et al., 1985; Semba et al., 1988). Beckstead et al. ( 1979) observed that tritiated
amino acid injections into VTA and medial SNc yield very light labeling of VP/SI;
however, no VP/SI labeling occurs when only SNc is involved. Voom et al. (1986)
showed that the VP/SI is dispersed with bundles of DA-IR fibers which branch out and
exhibit varicosities, indicating the VP/SI is a target for these fibers. By combining AChE
histochemistry with TH immunostaining, Martinez-Murillo et al. (1988) demonstrated that
large AChE-positive cell bodies are surrounded by dense TH-IR fibers. Many of the TH-
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IR terminals come in close contact with AChE-positive cell bodies, suggesting synaptic
contact. HRP injected into the vmGP/ic is retrogradely transported to ipsilateral SN and
LC, via fibers making up approximately 1% of the SN and 1% of the LC TH-IR cells
(Martinez-Murillo et al., 1988). Since LC contains noradrenergic cell bodies, these results
indicate that the VP/SI receives a noradrenergic input comparable to the DAergic input.
The above reports are in agreement with the findings of Zaborszky and associates
(Zaborszky et al., in press; Zaborszky et al., 1991; Zaborszky, 1989), who used light
microscopy (LM) and EM to visualize ventral forebrain neuronal elements in sections
double-labeled for ChAT and norepinephrine-specific, dopamine-P-hydroxylase (DPH),
or TH.

DPH-IR terminals closely appose cholinergic neurons throughout the basal

forebrain, particularly within the SL DBH-IR varicosities primarily are distributed around
distal cholinergic dendrites and form assymmetric synapses. The distribution of putative
synapses between TH-IR terminals and basal forebrain cholinergic neurons is similar to
that of DBH-cholinergic contacts. Putative contacts in the vmGP and the caudal GP/ic
region, however, exclusively are between TH-IR axons fibers and cholinergic neuronal
elements. TH-cholinergic synapses are symmetric and primarily are located on proximal
cholinergic dendrites or cell bodies.
Although TH immunostain also labels many DPH-IR axons, the different
distribution, arborization, and synaptic specializations of TH- and DPH- cholinergic
interactions suggests that DA-cholinergic contact does occur in the basal forebrain
(Zaborszky et al., in press; Zaborszky et al., 1991; Zaborszky, 1989)
Gustafson et al. (1989) also reported that DPH- and TH-positive axons possess
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different fiber characteristics and regional distributions. Thus, they surmised that at least
some of "the TH-IR fibers ... are DAergic and not noradrenergic." Furthermore, fibers
positively labeled for DARPP-32 (a DA- and cyclic AMP-regulated phosphoprotein
localized in dopaminoceptive brain regions) are "almost completely coextensive" with TH-

IR fibers within the basal forebrain at the level of the xac. In particular, they observed
that the VP contains a dense DARPP-32-IR terminal plexus (possibly originating in the
OT) as well as moderate innervation by TH-IR axons from the SNNTA (Gustafson et al.,
1989).
Confirming

Voorn

and

Zaborszky's

observations,

biochemical

and

electrophysiological data suggest that a DAergic input regulates VP/SI neurons. Guela
and Slevin (1989) and Napier and Potter (1989) demonstrated that DA is present within
the VP/SI and that bilateral 6-OHDA-induced destruction of the SN reduces DA and its
major metabolites in the VP/SI. Napier and associates (Napier et al., 1986; 1991a; Napier
and Potter, 1989) also reported that ~40% of VP/SI cells alter their firing rates in
response to locally-applied DA. Further experimentation revealed dose-related increases
in cell activity upon intravenous administration of apomorphine (Napier et al., 1991a) or

SKF 38393, and dose-dependent decreases in firing rate in response to the D2 receptorspecific agonist, quinpirole (Maslowski and Napier, 1989; 1991 ).
Autoradiographic studies show variable amounts of ligand binding to D 1
(Beckstead et al., 1988; Contreras et al., 1987; Mansour et al., 1990; Richfield et al.,
1989; Weiner et al., 1990) and D2 (Beckstead et al., 1988; Contreras et al., 1987; Gehlert
et al., 1985; Mansour et al., 1990; Richfield et al., 1989; Weiner et al., 1990) DAergic
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receptors in VP/SI slices, (see Tables 1 and 2). The majority report moderate to dense
binding to D1 but sparse or no binding to D2 receptors in this region. Conversely, D2
receptor mRNA has been visualized in VP/SI in moderate (Mansour et al., 1990) and low
(Weiner et al., 1990) amounts while Dl receptor rnRNA was not observed (Mengod et
al., 1991; Weiner et al., 1990). A lesion of the SN which does not change binding of
[3H]sulpiride to D2 receptors in VP/SI tissue homogenates (Guela and Slevin, 1989)
decreases DA content in both VP/SI and STR (Guela and Slevin, 1989; Napier and Potter,
1989).
Casamenti et al. (1986) observed that DAergic inputs influence the activity of VP
cholinergic neurons, resulting in changes of ACh release in the neocortex. Amphetamine
(i.p. injection) dose-dependently increases cortical ACh output (measured via the cortical
cup technique), an effect suppressed by electrolytic destruction of the VP and by a 6OHDA-induced lesion of the SN. This phenomenon also occurs after a large dose of
apomorphine (10 mg/kg i.p.) (Casamenti et al., 1986).

Utilizing in vivo brain

microdialysis and HPLC with electrochemical detection, Day and Fibiger (1992) measured
a significant increase in cortical ACh release following administration of 1.0 mg/kg
apomorphine. Pretreatment with SCH 23390 (0.3 mg/kg), but not raclopride (1.0 mg/kg),
completely blocked the increase. The Dl receptor agonist CY 208-243 likewise increased
cortical dialysate concentrations while D2 receptor agonists quinpirole and PHNO had no
effect (Day and Fibiger, 1992). These data coincide with the increase in cell firing rate
following systemic apomorphine (Napier et al., 1991a) and SKF 38393 (Maslowski and
Napier, 1989; 1991).
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In summary, DA fibers likely terminate in the VP/SI, DA and its metabolites exist
in this region and are reduced following a 6-OHDA lesion of the SN, both receptor
subtypes are present in the VP/SI, and VP/SI cells are sensitive to DA and DA agonists.
These data support the hypothesis that the VP/SI is a dopaminoceptive brain region. The
dense population of cortically-projecting cholinergic cells in the VP/SI is involved in
learning and memory and appears to be critical for the development of reinforced
behaviors. Amphetamine and apomorphine can increase ACh output from VP/SI neuron
terminals. Therefore, the possibility that DA modulates cholinergic cells in the VP/SI
warrants further investigation.
The present study was adopted: 1.) to investigate whether DA receptors in the
basal forebrain, particularly the VP/SI, adapt to chronic DA receptor antagonist treatment;
and 2.) to determine if cholinergic neurons in the VP/SI respond to the chronic
antagonism by altering ChAT in their terminal regions. Rats were divided into three
groups (30 rats/group), receiving either the D2 receptor-specific antagonist sulpiride
(Jenner et al., 1978; Jenner and Marsden, 1982; Peselow and Stanley, 1982; Trabucchi
et al., 1975; Worms, 1982), Dl specific antagonist SCH 23390 (Billard et al., 1984;
Hyttel, 1983, 1984; Iorio et al., 1983; O'Boyle and Waddington, 1987), or vehicle
injections for 21 days. (A treatment duration of 21 days commonly is used to induce
physiological conditions associated with chronic drug administration [Gandolfi et al.,
1988; Grebb et al., 1990; Memo et al., 1987; Satoh et al., 1987].) On day 23, the rats
were killed and their brains removed, hand-dissected, and frozen (-70°). ChAT activity,
thought to reflect changes in cholinergic neuron activity (Kuhar, 1976; Watson et al.,
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1985), was measured in cortical tissues. Changes in VP/SI DA receptor number were
measured with the DI-selective ligand [3H]SCH 23390 (Creese and Chen, 1985) and the
D2-selective ligand [3H]spiperone (Seeman 1980). The above parameters also were
measured in the STR and septohippocampal system, where DA-ACh interactions are wellcharacterized.
Another study also was undertaken to ascertain that acute DA antagonist treatment
did not down-regulate DA receptors.

A separate group of 18 rats received single

injections of either SCH- 23390, sulpiride, or vehicle at the same dose and volume as that
given during the chronic study.

Radiolabeling of DI or D2 sites subsequently was

performed on striatal tissue taken from these animals 48 hours after injection.

Table 1. REGIONAL Dl DOPAMINE RECEPTOR BINDING
AUTHOR
Camps et al., 1990

LIGAND

CAUDATE; PUTAMEN

VP/SI

GP

GP[e£]

SEPTUM

[3HJSCH 23390, lnM

757.13±77.36

ND

132.35±25.27

292.63±36.07

60.0±3.5

Rat

527.3±52.0

ND

184.2±17.8

358.3±107.6

86.6±2.3

Guinea pig

612.4±41.15

ND

106.3±22.3

289.6±7.3

82.1±19.2

Cat

597 .0±60.0; 509 .4±66.0

ND

64.9±60.0

349.3±157.0

100.7±65.1

Monkey

420.6±12.34; 372.3±41.5

ND

78.5±49.1

206.2±77.8

ND

Human

267 .5±21.8; 251±21.3

ND

27.8±10.5

102.9±18.4

ND

SPECIES METHOD
Mouse

Quant

Mansour et al., 1990

Rat

Qual

[3HJSCH 23390, 4.4nM

Dense

Dense

Moderate

ND

Light

Weiner et al., 1990

Rat

Qual

Dl specific

ND

None

Considerable

ND

Light

Richfield et al., 1989

Rat

Quant

[3HJSCH 23390

1342±44

689±26

192±33

600±48

79±34

Beckstead et al., 1988*

Cat

Quant

[3HJSCH 23390, 2nM

279-362; 219-330

135±15

0

217±6

ND

Contreras et al., 1987

Rat

Qual

[3HJSCH 23390, lOnM

Very dense

Dense

Light

ND

Light

Data are represented as the mean±S.E.M. in fmol/mg protein or *fmol/mg tissue. Quant, quantitative autoradiography; Qual, qualitative autoradiography; ND,
not determined.

Table 2. REGIONAL D2 DOPAMINE RECEPTOR BINDING

AUTHOR
Camps et al., 1990

SPECIES METHOD

LIGAND

CAUDATE; PUTAMEN

VP/SI

GP

GP[ep_J

SEPTUM

[3H]CV 205502, lnM

477.41±42.13

ND

67.5±27.5

ND

52.0±16.5

Rat

282.11±15.2

ND

35.72±5.01

25.22±9.41

56.21±10.4

Guinea pig

213.54±17.37

ND

31.36±6.1

20.2

38.21±6.13

Cat

335.08±26.07; 326.8±11.49

ND

126.63±38.45

55.35±.62

50.83±2.84

Monkey

255.66±7.37; 272.66±13.89

ND

17.18±1.29

14.33±9.79

ND

Human

151.4±11.6; 163.8±13.3

ND

44.1±9.9

31.6±6.5

ND

Mouse

Quant

Mansour et al., 1990

Rat

Qual

[3H]raclopride, 5.7nM

Dense

None

Light

ND

Light

Weiner et al., 1990

Rat

Qual

D2 specific

ND

None

Light

ND

Light

Guela & Slevin, 1989

Rat

Homog

[3H]sulpiride, lnM

ND

58.2

ND

ND

ND

[3H]sulpiride, 15nM

ND

547.2±80.1

ND

ND

ND

Richfield et al., 1989

Rat

Quant

[3H]spiperone

562±18

70±14

28±8

19±14

59±11

Beckstead et al., 1988*

Cat

Quant

[3H]spiperone, 2nM

154-248; 190-222

0

80±8

35±4

ND

Contreras et al., 1987

Rat

Qual

[3H]sulpiride, lOnM

Very dense

Light

Light

ND

Light

Gehlert & Wa.'llsley 1985* Rat

Quant

[3H]sulpiride, 15nM

17.3±0.50

1.18±0.07

ND

ND

1.15±.04

Data are represented as the mean±S.E.M. in fmol/mg protein or *fmol/mg tissue. Quant, quantitative autoradiography; Qual, qualitative autoradiography; Homog,
tissue homogenate; ND, not determined.

MATERIALS AND METHODS

Animals

Male Sprague Dawley rats (Harlan Laboratories) weighed approximately 220
grams at the outset of the study and reached approximately 300 grams at the termination
of the treatment. The animals were housed in groups of 2-3 per cage, with food (Wayne
Lab Blox rat chow) and water provided ad libitum. The facility was maintained at 23250C with 12:12 hour light:dark cycles (0700 on, 1900 off).

Upon arrival to the

laboratory, the rats were acclimated for at least one week prior to experimental use.

Chronic Drug Treatment

At a constant time in the afternoon (between 1:00-3:00 p.m.), 90 rats received a
subcutanous injection of 0.25 mg/kg SCH 23390 (Schering), SCH 23390 vehicle, 12.5
mg/kg sulpiride (Sigma), or sulpiride vehicle, once daily, for 21 days. No injections were
given on day 22.

Following the 48-hour washout, animals were sacrificed by

decapitation, the brains removed, and the appropriate tissues dissected on ice and frozen
at -70°C for future analysis.
The injection volume for all treatments was 1 ml/kg. Drugs were prepared in
advance as follows: a sufficient quantity of SCH 23390 (as salt) was dissolved in a
solution of 0.3% tartaric acid and 1.5% ethyl alcohol, such that the final concentration
was 0.25 mg/ml. A sufficient quantity of sulpiride was dissolved in a drop of glacial
24
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acetic acid plus distilled water such that the final drug concentration was 12.5 mg/ml.
The sulpiride solution next was buffered to physiological pH with 1-2 drops of 12N
sodium hydroxide. The pH of all drug and all vehicle solutions ranged from 7 .0 to 7 .5.
The SCH 23390 and sulpiride doses chosen were those which blocked respectively
SKF38393- and quinpirole-induced changes in VP/SI neuron firing rates during
electrophysiologic studies in our laboratory (Maslowski and Napier, 1991; Napier, 1991).
These doses also are sufficient to reverse apomorphine-induced hyperactivity in rats (Iorio
et al., 1983; Kohler et al., 1979; Ogren et al., 1986).

Acute Drug Treatment
D 1 and D2 receptor binding following acute drug treatment and 48-hour washout
additionally was performed in STR. A total of eighteen rats received one subcutaneous
injection of either SCH 23390 (n=6), sulpiride (n=6), or vehicle (n=6) at the same dose
and volume as used in the chronic study.

Forty-eight hours later, the animals were

decapitated and the brains dissected and frozen.

[3H]SCH 23390 and [3H]spiperone

binding each were determined in three rats per group. This was done to verify that a
single dose did not down-regulate DA receptors and that the tissue washes employed in
the assay protocol adequately removed any residual drug.

Tissue Dissection
Brain regions are described in terms of coordinates given in the atlas of Paxinos
and Watson (1986) and by structural landmarks.

Frontoparietal cortex, anterior

cingulate, septum, and STR were taken from a coronal section between 1.7 and 0.26mm
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posterior to bregma.

In relation to the ventral surface of the brain, the anterior cut

occurred in the center of the olfactory tubercles and the posterior cut just before the optic
chiasm, exposing the xac.
The next section caudally extended approximately 1.5mm from xac, ending
immediately behind the widest part of the optic chiasm (about 1.3mm posterior to
bregma). From this slice, several regions were obtained: VP/SI; small squares of tissue
were taken from beneath the xac, from l-4mm lateral to midline. The knife was slanted
to accommodate the lateral shift of this nucleus. GP; the rounded tissue was peeled from
the area above the xac and between the ic and STR. The dissection was such that more
tissue was obtained from the posterior side of the slice, reflecting the GP's increase in
size at more caudal positions. A similar dissection was described by Geula and Slevin
(1989).
The next tissue block caudally extended about 1mm from the previous cut and
contained the amygdala. At this point the hippocampus is present although not fully
formed. The region where the ventrolateral aspect of the brain folds under temporal
cortex was dissected.
The hippocampus was removed from the remaining brain.

Radioligand Binding in STR, Septum, VP/SI, and GP
DJ receptor binding with [3H]SCH 23390

The D1 receptors were labeled using the DI-selective ligand [3H]SCH 23390
(Creese and Chen, 1985), according to the method of Hess et al. (1986). In brief, tissue
from STR, septum, VP/SI and GP was homogenized using a Polytron homogenizer
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(setting 7, 10 seconds) in 40 volumes of ice-cold 50mM Tris-HCI buffer (pH 7.7 at
25°C). Samples subsequently were centrifuged (48,000 x gravity, 15 minutes, 4°C) and
the pellets resuspended and washed three times. The final resuspension was into assay
buffer consisting of 50mM Tris-HCI, 5mM MgSO4 , 0.5mM ethylenediaminetetra-acetic
acid (EDTA), in 0.02% ascorbic acid at a tissue concentration of 10.0mg wet weight/ml
buffer. Incubations were initiated by adding tissue homogenate (0.10ml) to quadruplicate
tubes containing [3H]SCH 23390 (Acute study: 2.8nM; Chronic study: STR and VP/SI,
2.3nM; GP and septum, 1.9nM) in the absence and presence of (+)-butaclamol (10-6M)
to define specific binding. All tubes contained 40nM ketanserin to preclude binding of
radioligand to 5HT2 receptors, yielding a 3ml final assay volume. Tubes were incubated
for 30 minutes at 37°C, filtered over Whatman GF/C filters under vacuum using a
Brandell cell harvester, and then washed rapidly three times with 5ml of Tris buffer (15ml
total).

Radioactivity trapped on the filters was measured by liquid scintillation

spectroscopy (Beckman) at an efficiency of approximately 50%.

Ligand binding is

reported as fmol ligand bound/mg protein.

D2 receptor binding with [3H]Spiperone

The D2 receptors were labeled using the D2-selective ligand [3H]spiperone
(Seeman 1980), as previously described by Norman et al. (1987). Again, STR, septum,
VP/SI, and GP tissues were homogenized, washed, and resuspended in assay buffer at the
concentration of 10.0mg wet weight tissue/ml buffer. Incubation began by the addition
of tissue homogenate (0.10ml) to quadruplicate tubes containing [3H]spiperone (Acute
study: 0.67nM; Chronic study: STR, 0.5nM; VP/SI, 1.5nM; GP and septum, 0.78nM) and
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40nM ketanserin (to preclude binding of radioligand to 5HT2 receptors) at a total assay
volume of 3ml. (+)-Butaclamol ( 1o- 6 M) was used to determine specific binding. Tubes
were incubated for 40 minutes at 37°C, filtered over Whatman GF/C filters, and washed
3 times with 5ml Tris buffer (15ml total).

Radioactivity trapped on the filters was

measured by liquid scintillation spectroscopy at an efficiency of approximately 50%.
[3H]spiperone binding is reported as fmol ligand bound/mg protein.
Protein content of each homogenate was determined by the method of Lowry et
al. (1951).

ChAT Activity in Cortex, Hippocampus, Amygdala, and Striatum

ChAT activity was estimated according to Fonnum ( 1969) with modifications
made in our laboratory.
Several solutions were prepared in advance. 1.) Sodium phosphate buffer (75rnM,
pH 7.4): Sodium phosphate monobasic solution (5.850g/L) was added to sodium
phosphate dibasic solution (10.647g/L) until the buffer reached a pH of 7.4. 2.) Buffer
substrate: Into 10ml sodium phosphate buffer was added NaCl 0.351g, MgCl2 -6H20
0.0813g, physostigrnine 0.0083g, AcetylCoenzymeA (AcCoA) 0.008g, choline iodide
0.0231g, and bovine serum albumin 0.005g. The solution was frozen and stored at -20°C
in 1ml aliquots. 3.) Heptanone solution: 75mg sodium tetraphenylboron was dissolved
per ml 3-heptanone. This was prepared the day of the assay.
Tissue from frontoparietal cortex, anterior cingulate, STR, hippocampus, and
amygdala was homogenized in 20 volumes (40 volumes for STR) of sodium phosphate
buffer. Next, homogenates (10µ1) were pipetted into the bottom of triplicate microfuge
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tubes kept on ice.

Buffer substrate was thawed and spiked with [3H]AcCoA (20µ1

[3H]AcCoA per ml buffer substrate). Ten µI of the [3H]buffer substrate was added to
each tube. Tubes were tapped to ensure adequate mixing and then incubated for 30
minutes in a 37°C water bath with constant shaking.

Incubation was terminated by

addition of 150 µI heptanone solution to each tube and subsequent centrifugation to
extract the organic phase. Radioactivity in 100 µI of the organic phase was counted by
liquid scintillation spectroscopy. ChA T activity is reported as nmol ACh formed/mg
protein/minute.
Protein content of the tissue homogenate was determined according to the method
of Lowry et al. (1951).

Statistics

For the radioligand binding experiments, significant differences between the mean
fmol binding/mg protein for each drug treatment group and vehicle control was
determined by one-way analysis of variance (ANOVA) and post hoc Student-NeumanKeul' s test. These analyses also were used to find significant differences between the
mean ChAT activity (in nmoles ACh formed/mg protein/hour) of each treatment group
and vehicle control. The minimum criterion for significance was P<0.05.

RESULTS

Radioligand Binding

Preliminary Experiments
To establish the nature of [3H]SCH 23390 and [3H]spiperone binding in our
laboratory, preliminary experiments were performed (data not shown) on untreated rat
STR according to the protocols described in "Materials and Methods". Binding was
evaluated as a function of radioligand concentration. Saturation of specific sites was
achieved while nonspecific binding increased linearly over the concentration ranges tested.
Scatchard analysis indicated the presence of a single binding site for [3H]SCH 23390 with
a k0 of 0.9 nM and a Bmax of 448 fmol/mg protein [r=-0.98]. This is consistent with other
reports in which the k0 ranges from 0.3 to 1.1 nM (Billard et al., 1984; Creese and Chen,
1985; Hess et al., 1986; Lappalainen et al., 1990; McGonigle et al., 1989) and the Bmax
ranges from <500 to 1538 fmol/mg protein (Billard et al., 1984; Camps et al., 1990; Hess
et al., 1986; Lappalainen et al., 1990; Richfield et al., 1989).

[3H]Spiperone also

demonstrated binding to one site with a k0 of 0.18 nM and a Bmax of 27 6 fmol/mg protein
[r=-0.94]. Reported k0 values for this ligand range from 0.03 to 1.3 nM while Bmax
ranges from 135 to 600 fmol/mg protein.

(Memo et al., 1980; Norman et al, 1987;

Seeman 1980). Because our numbers generally fell within the ranges observed by others,
we proceeded with the experiments described in this thesis.
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Acute Studies
D 1 and D2 receptor binding was performed on rat STR taken 48 hours after one
subcutaneous injection of vehicle, SCH 23390 (0.25 mg/kg, s.c.), or sulpiride (12.5 mg/kg,
s.c.). This was done to verify that a single injection of drug did not down-regulate DA
receptors and that any residual drug present in basal forebrain tissue was adequately
removed by repeated tissue washings (as described in "Materials and Methods"). Results
are summarized in Table 3.

Striatal [3HJSCH 23390 sites

As shown in Table 3, a single injection of SCH 23390 did not alter D 1 receptor
binding from vehicle control. This indicates that a single treatment does not downregulate D 1 receptors and that 48 hours is an adequate drug washout period. This is
consistent with the findings of Lappalainen et al. ( 1990), who reported that residual SCH
23390 was absent from the brain tissue of rats 16 hours after the last chronic treatment
with the drug. A two-day washout also is compatible with the short plasma half-life (2030 minutes) of SCH 23390 (Kilts et al., 1985).
Congruent with sulpiride's selectivity for the D2 receptor, (Jenner et al., 1978;
Jenner and Marsden, 1982; Peselow and Stanley, 1982; Trabucchi et al., 1975; Worms,
1982) sulpiride had no effect on [3H]SCH 23390 binding to D1 receptors.

Striatal [3H]spiperone sites

D2 receptor binding performed 48 hours after acute sulpiride treatment likewise
did not differ from vehicle control. Since the plasma elimination half-life of sulpiride is
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relatively short, approximately 1-2 hours (Yamada et al., 1990), these data suggest that
the residual sulpiride concentration is negligible 48 hours after a single injection. Thus,
a 2-day washout period appears sufficient to prevent sulpiride interference with
[3H]spiperone binding to D2 receptors. These data furthermore indicate that a single dose
of sulpiride does not upregulate D2 receptors.
Consistent with its D1 selectivity, (Billard et al., 1984; Hyttel, 1983, 1984; Iorio,
1983; O'Boyle and Waddington, 1987) SCH 23390 did not significantly alter
[3H]spiperone binding to striatal homogenates (Table 3).

Chronic Studies

Rats received daily injections of either SCH 23390 (0.25 mg/kg, s.c.), sulpiride
(12.5 mg/kg s.c.), or vehicle for 21 days. Following a two-day washout, the animals were
killed and appropriate brain regions were removed and frozen (-70°C) for future analysis.
Thirty rats were assigned to each group: 24 rats provided brain tissue for the previously
described experiments while the brain tissue of the remaining 6 rats in each group served
as a back-up in the event that:

1.) a test had to be repeated; or 2.) opportunities to

perform additional experiments arose. D1 receptors were labeled with [3H]SCH 23390
and D2 receptors with [3H]spiperone.

Results are summarized in Tables 4 and 5,

respectively. The data obtained from STR of rats subjected to chronic vehicle injection
respectively are within the ranges of Bmax values reported for these radioligands in
untreated STR (Billard et al., 1984; Creese and Chen, 1985; Hess et al., 1986;
Lappalainen et al., 1990; Norman et al., 1987; Seeman 1980). Our data from GP and
septum are comparable to the corresponding values (Tables 1 and 2) reported by Camps
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et al. (1990). This indicates that: 1.) the radioligand assay worked adequately; and 2.)
in terms of receptor number, the experimental method itself did not induce a response.
Consequently, we used the DA receptor concentrations present after vehicle treatment as
the standard by which treatment responses could be identified.

Chronic SCH 23390 treatment
Chronic SCH 23390 (0.25 mg/kg/day) treatment significantly increased (~40%)
the binding of [3H]SCH 23390 to Dl receptors in STR [F<2, 15)=5.31, P=0.018, one-way
ANOVA; q=4.296, post hoc Student-Neuman-Keul's test] (Table 4). This is in agreement
with several authors who reported selective upregulation of striatal Dl receptors after 1221 days of SCH 23390 followed by 2-8 days withdrawal (Barone et al., 1988; Creese and
Chen, 1985; Grebb et al., 1990; Memo et al., 1987). Dl binding in septum, VP/SI, and
GP was not significantly changed from control levels, however. Acute studies by Zhu
et al. ( 1990) similarly showed that rat STR, but not septum, responds to D 1 receptor
blockade by SCH 23390 (Zhu et al., 1990).
During the present research, in contrast, there was no upregulation of
[3H]spiperone sites in STR or any basal forebrain region after 21-day treatment with SCH
23390 (Table 5).
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Chronic sulpiride treatment

Chronic sulpiride (12.5 mg/kg/day) did not alter [3H]spiperone binding to D2
receptors in any brain region tested (Table 5). Striatal insensitivity to chronic sulpiride
administration has been described by other researchers. Rupniak et al. (1984) and Jenner
and Marsden (1987) reported that [3H]spiperone binding in rat STR is unchanged after
animals receive 102-109 mg/kg sulpiride daily, for 12 months, via drinking water. Satoh
et al. (1987) observed that when rats are injected i.p., daily sulpiride at 100 mg/kg (21
days) significantly increases the

Bmax

for [3H]spiperone-labeled sites; but doses of 1 or

10 mg/kg/day are ineffective.

Missale et al. (1990) likewise observed that chronic

sulpiride in low doses (4 mg/kg) does not induce a change in striatal DA recognition sites
after 21 days (Missale et al., 1990). Striatal D2 sites similarly are insensitive to chronic
treatment with low doses of the sulpiride analog, raclopride (See et al., 1990).
Likewise, following chronic sulpiride, the number of [3H]SCH 23390 sites in each
region was not significantly different from that in the corresponding control (Table 4).
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ChAT Activity Measurement
In conjunction with the radioligand binding experiments performed on cholinergic
cell body regions (i.e., MS, VP/SI, GP, and STR), ChAT activity in terminal regions (i.e.,
frontoparietal cortex, anterior cingulate, amygdala, hippocampus, and STR) was measured
for its response to chronic antagonist treatment.

Tissue obtained from animals that

received vehicle for 21 days yielded ChAT activity values similar to those previously
reported for the corresponding brain areas from untreated rats (Rupniak et al., 1986;
Chrobak et al., 1987; 1988). As with the receptor binding data, this verifies the reliability
of the assay and indicates that ChAT was unaffected by the experimental protocol.
The vehicle group served as the control to which the results from drug-treated rats
were compared. The ChAT responses to chronic treatment are given in Table 6.
Chronic SCH 23390 treatment significantly increased ChAT activity in
frontoparietal cortex [F<2•65l=5.11, P=0.009, one-way ANOVA; q=4.521, post hoc StudentNewman-Keul's test] and amygdala [F<2,65l=l 1.57, P=0.000, one-way ANOVA; q=6.723,
post hoc Student-Neuman-Keul's test] but did not affect ChAT levels in anterior cingulate

or hippocampus. Striatal ChAT appeared to be reduced, but did not reach significance
[F0 .10l=4.31, P=0.065, one-way ANOVA; q=2.937,post hoc Student-Neuman-Keul's test].
In contrast, ChAT in the anterior cingulate and hippocampus responded to longterm sulpiride administration.

Respectively, those regions demonstrated increased

[F<2•64l=3.39, P=0.040, one-way ANOVA; q=4.26, post hoc Student-Neuman-Keul's test]
and decreased [F<2,67l=4.13, P=0.020, one-way ANOVA; q=4.037, post hoc StudentNeuman-Keul's test] activity compared to vehicle control.

Amygdala ChAT also
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appeared to be reduced following chronic sulpiride, but a significant response was not
achieved [F0 ,43l=3.15, P=0.08, one-way ANOVA; q=2.51, post hoc Student-NewmanKeul's test]. ChAT in frontoparietal cortex and striatum was unaffected by sulpiride
treatment (Table 6).

Table 3. STRIAT AL Dl AND D2 SITES FOLLOWING SINGLE INJECTIONS OF DA RECEPTORSELECTIVE ANTAGONISTS: COMPARISON TO VEHICLE CONTROL

Treatment
Ligand

Vehicle

SCH 23390

Sulpiride

[3H]SCH 23390 (2.8 nM)

486±53
n=3

560±89
n=3

464±179
n=3

[3H]Spiperone (0.67 nM)

219±20
n=3

298±50
n=3

247±68
n=3

Data are represented as the mean±S.E.M. in fmoles/mg protein. No significant differences from vehicle
control were detected. [3H]SCH 23390: F< 2.6>=0.18, P=0.842, one-way ANOVA; q=0.803, post hoc
Student-Newman-Keul's test. [3H]Spiperone: F< 2•6>=0.065, P=0.555, one-way ANOVA; q=l.592, post hoc
Student-Newman-Keul's test. n indicates the number of tissues per group.
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Table 4. [3H]SCH 23390 BINDING TO Dl RECEPTORS: RESPONSE TO CHRONIC
ANTAGONISM
Treatment
Vehicle

SCH 23390

Sulpiride

Striatum

475±38.4
n=6

*667±50.9
n=6

507±43.9
n=6

Septum

64.2±14.6
n=6

50.9±16.5
n=5

62.1±3.60
n=5

Ventral Pallidum/Substantia
Innominata

193±33.1
n=6

232±30.1
n=6

170±30.2
n=6

Globus Pallidus

226±25.4
n=6

216±40.9
n=6

200±40.0
n=6

Tissue

Data are represented as the mean±S.E.M. in fmoles/mg protein. * indicates significant difference from
vehicle control. Striatum: F< 2•15l=5.3 l, P=0.018, one-way ANOV A; q=4.296, post hoc Student-NeumanKeul's test. Septum: F< 2•14l=0.29, P=0.756, one-way ANOVA; q=l.002, post hoc Student-Newman-Keul's
test. VP/SI: F< 2,15l=l.01, P=0.389, one-way ANOV A; q=l.985, post hoc Student-Newman-Keul's test. GP:
F<2,15J=0.13, F=0.878, one-way ANOVA; q=0.717, post hoc Student-Newman-Keul's test. n indicates the
number of tissues per group.
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Table 5. [3H]SPIPERONE BINDING TO D2 RECEPTORS: RESPONSE TO CHRONIC
ANTAGONISM
Treatment
Tissue

Vehicle

SCH 23390

Sulpiride

Striaturn

203±22.3
n=6

205±34.8
n=6

207±18.9
n=6

Septum

18±3.6
n=lO

16±1.5
n=ll

24±3.6
n=12

Ventral Pallidum/Substantia
Innominata

77±18
n=lO

82±19
n=lO

68±19
n=8

Globus Pallidus

40±6.5
n=ll

40±16
n=lO

34±4.3
n=9

Data are represented as the mean±S.E.M. in fmoles/mg protein. Striaturn: F< 2•15l=0.01, P=0.995, one-way
ANOVA; q=0.140, post hoc Student-Newman-Keul's test. Septum: F< 2•30l=2.12, P=0.138, one-way
ANOVA; q=2.710,post hoc Student-Newman-Keul's test. VP/SI: F< 2•25l=0.14, P=0.868, one-way ANOVA;
q=0.750, post hoc Student-Newman-Keul's test. GP: F< 2 •27 l=0.09, P=0.911, one-way ANOVA; q=0.549,
post hoc Student-Newman-Keul's test. n indicates the number of tissues per group.
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Table 6. ChAT RESPONSE TO CHRONIC DOPAMINE RECEPTOR ANTAGONISM
Treatment
Tissue

Vehicle

SCH 23390

Sul2iride

Frontoparietal Cortex

72.8±3.14
n=23

*87.4±3.65
n=22

79.7±2.87
n=23

Amygdala

126.8±5.08
n=22

*181.3±7.80
n=23

147.4±10.3
n=23

Anterior Cingulate

133.6±5.40
n=22

131.3±3.13
n=23

* 145.8±3.92
n=22

Hippocampus

49.1±2.08
n=24

44.3±2.42
n=23

*40.9±1.50
n=23

Striatum

164.5±8.98
n=6

141.3±6.62
n=6

156.5±7.91
n=6

Data are represented as the mean±S.E.M. in nmoles ACh formed/hourmg protein. * indicates significant
difference from vehicle control. Frontoparietal Cortex: F< 2•65l=5.1 l, P=0.009, one-way ANOVA; q=4.521,
post hoc Student-Newman-Keul's test. Amygdala: F< 2.65 l=l 1.57, P=0.000, one-way ANOV A; q=6.723, post
hoc Student-Neuman-Keul's test. Anterior Cingulate: F< 2•64l=3.39, P=0.040, one-way ANOV A; q=4.26, post
hoc Student-Neuman-Keul's test. Hippocampus: F< 2•67l=4.13, P=0.020, one-way ANOV A; q=4.037, post hoc
Student-Neuman-Keul's test. Striatum: F< 2•15l=2.22, P=0.143, one-way ANOV A; q=2.935, post hoc
Student-Newman-Keul's test. n indicates the number of tissues per group.

40

DISCUSSION

The outcome of the present research indicates that terminal regions of basal
forebrain cholinergic neurons (i.e., anterior cingulate, frontoparietal cortex, amygdala, and
hippocampus) respond to chronic DA receptor antagonism with changes in ChAT activity.
The inhibitory effect on the septohippocampal pathway and the stimulatory effect on the
VP/SI-cortical projection appears to distinguish the two systems. Coincident changes in
the number of DA receptors located in the cholinergic cell body regions (i.e., septum,
VP/SI, GP) were not detected.
The present data additionally suggest that striatal interneurons react differently to
chronic DA antagonist treatment than do cholinergic projection neurons of the basal
forebrain. The STR responded to D 1 antagonism with an increase of [3H]SCH 23390
sites. In contrast, no changes in [3H]spiperone sites occurred following chronic sulpiride.
This lack of response to sulpiride has been reported by other researchers (Jenner and
Marsden, 1987; Missale et al., 1990; Rupniak et al., 1986; Satoh et al., 1987). Neither
drug treatment altered striatal ChAT levels, which may have been a consequence of the
small sample size available for striatal ChAT measurement.
Tissue supersensitivity after long-term exposure to a DA antagonist can be
characterized by an increase in receptor number and enhanced electrophysiological,
enzyme, or behavioral responses to DA or DA receptor agonists (Bloom et al., 1981;
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Creese and Sibley, 1980; Page et al., 1984; Gnegy and Costa, 1980; Jenner and Marsden,
1987; Memo et al., 1987). Thus, the selective upregulation of striatal [3H]SCH_ 233390
sites after 21-days' SCH 23390 administration likely represents a supersensitive response.
No changes in receptor number occurred in septum, VP/SI, or GP after chronic SCH
23390 or sulpiride, demonstrating that these areas are regulated differently than STR. It
is possible that the small number of basal forebrain DA receptors precluded accurate
detection of quantitative changes.

It also is possible that the amounts of antagonist

reaching these regions were insufficient to induce receptor upregulation, but were
adequate to alter DAergic influence.
Despite the negative radioligand binding results, chronic DA antagonist treatment
appeared to make basal forebrain cholinergic terminals more sensitive to endogenous DA.
ChAT activity in frontoparietal cortex and amygdala increased following chronic SCH
23390 treatment while chronic sulpiride augmented ChAT in anterior cingulate.
Conversely, chronic sulpiride treatment reduced hippocampal ChAT activity.
Several research groups also have observed DA's apparent stimulatory effect on
telencephalic cholinergic terminals.

Ho and Loh (1972) demonstrated that daily

intracisternal injections of DA given to rats over four days significantly increase ChA T
activity in both the frontal cortex and the rest of the brain. Casamenti et al. ( 1986)
reported that intraperitoneal amphetamine dose-dependently increases cortical ACh output
(measured via the cortical cup technique), an effect suppressed by electrolytic destruction
of the VP and by a 6-OHDA-induced lesion of the SN.

They also observed this

phenomenon with a large dose of apomorphine (10 mg/kg; Casamenti et al., 1986).
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During preliminary experiments, Day and Fibiger (1991) similarly observed that
amphetamine (2 mg/kg) increased frontal cortical ACh output by 180% (measured by in

vivo

brain microdialysis).

This increase was completely blocked by SCH 23390

administration (0.3 mg/kg) but only partially attenuated by haloperidol (0.15 mg/kg).
Interestingly, local application of amphetamine (10-5M) did not alter ACh release (Day
and Fibiger, 1991). Day and Fibiger (1992) also noted that apomorphine elicited an
increase in ACh release (measured by in vivo

brain microdialysis and HPLC with

electrochemical detection), but at a smaller dose than that used by Casamenti and
associates: Cortical ACh output increased 120% following a 1.0 mg/kg dose.

The

apomorphine response was completely blocked by SCH 23390 (0.3 mg/kg) but not by
raclopride (LO mg/kg). The Dl receptor agonist CY 208-243 likewise increased cortical
dialysate concentrations of ACh by 80% while D2 receptor agonists quinpirole and PHNO
had no effect on cortical ACh release (Day and Fibiger, 1992).
DA's apparent inhibitory effect on hippocampal ChAT following chronic sulpiride
agrees with earlier reports that DA exerts a tonic inhibitory influence on
septohippocampal cholinergic neurons (Durkin et al., 1986; Gilad et al., 1986; Robinson
et al., 1979). Acute DA blockade with intraseptal haloperidol, or disruption of septal DA
innervation with 6-OHDA, increases ACh turnover in hippocampus (Robinson et al.,
1979).

DA receptor antagonists (e.g., haloperidol and sulpiride) also increase

hippocampal HAChU (Durkin et al., 1986; Gilad et al., 1986), while DA receptor agonists
(e.g., apomorphine) reduce hippocampal ACh turnover (Robinson et al., 1979).
The present data indicate that chronic DA receptor blockade can alter DA's
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influence on basal forebrain neuron terminals in the absence of DA receptor upregulation.
Similar phenomena have been reported elsewhere.

For example, twelve months'

sulpiride administration increases striatal cyclic AMP formation but does not alter the
number of striatal [3H]spiperone sites (Jenner and Marsden, 1987). Limbic area and
striatal homovanillic acid (HV A) and 3,4-dihydroxyphenylacetic acid (DOPAC) levels,
but not [3H]spiperone sites, are sensitive to 21 days' sulpiride treatment (1, 10, or 100
mg/kg; Satoh et al., 1987). Because so few chronic studies have examined receptor
number in tandem with other measures of cell function, the necessity of an increase in
receptor number for the manifestation of tissue supersensitivity is unclear.
The involvement of other neurotransmitter systems in the observed alterations in
ChAT activity also must be considered. SCH 23390 possesses marginal affinity for al
and a2 adrenergic, muscarinic, histaminergic, and 5-HT1c serotonergic receptors. The
affinity of SCH 23390 for 5-HT2 sites, however, is in the nanomolar range (Clark and
White, 1987). As such, the possibility exists that the observed effects on cortical and
amygdala ChAT activity following SCH 23390 treatment were due, in part, to changes
in 5-HT transmission. For example, Bijak and Smialowski (1987) observed that repeated
SCH 23390 administration (0.5 mg/kg) induces functional supersensitivity of central 5-HT
receptors (increases quipazine-induced head twitches; Bijak and Smialowski, 1987). In
contrast, investigators who measured 5-HT and 5-hydroxy indoleacetic acid (5-HIAA)
levels in prefrontal cortex, frontal cortex, dorsal and medial raphe, VTA, SN, caudate, and
NA reported that no changes occur after chronic SCH 23390 administration (Gandolfi et
al., 1988; Lappalainen et al., 1990).
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It also is unlikely that the changes in anterior cingulate and hippocampal ChAT
after chronic sulpiride were induced by an interaction between sulpiride and non-DAergic
receptors.

Studies have shown that competition between sulpiride and radioligands

labeling norepinephrine, 5-HT, ACh, or histamine receptors is negligible, with k; values
for sulpiride ranging from 1,000 - > 10,000 nM (Jenner and Marsden et al., 1982). GAD
activity and [3H]flunitrazepam binding to GABA receptors in STR and SN, appear
unchanged by sulpiride treatment, as does [3H]quinuclidinylbenzilate ([3H]QNB) binding
to striatal muscarinic receptors (Jenner and Marsden, 1987). Sulpiride does not alter
norepinephrine or 5-HT turnover, nor does it block tryptophan-induced myoclonic activity
in guinea pigs, (for review see Jenner and Marsden, 1982). Further investigation is
necessary to determine the contributions of other neurotransmitters and peptides to DAACH interactions in the basal forebrain.
Because Dl receptors exist in rat frontoparietal cortex and amygdala (Camps et
al., 1990; Contreras et al., 1987; Mansour et al., 1990; Nisoli et al., 1988; Weiner et al.,
1990) as well as other cortical regions (Mansour et al., 1990), the possibility that SCH
23390 acts exclusively on these areas rather than via D 1 receptors located on or near
cholinergic cell bodies in the basal forebrain cannot be excluded; however, evidence that
chronic SCH 23390 does not affect cortical DA systems has been reported. Memo et al.
(1987) observed that in rats, 60-days' SCH 23390 administration enhances the ability of
SKF 38393 to stimulate adenylate cyclase (tVma,) in STR but not in cortex or
hippocampus. Lappalainen et al. ( 1990) found that HV A concentration in the caudate is
reduced while that in prefrontal cortex is unchanged when rats receive SCH 23390 for 18
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days. DA levels in both regions remain unaffected by the treatment (Lappalainen et al.,
1990).
The possibility also exists that sulpiride acts exclusively on D2 receptors in the
anterior cingulate and hippocampus (Camps et al., 1990; Contreras et al., 1987; Gehlert
and Wamsley, 1985; Mansour et al., 1990); however there is evidence to suggest
otherwise.

Moghaddam and Bunney (1990) demonstrated that acute sulpiride doses

ranging from 20 to 100 mg/kg i.v. do not affect DA outflow in rat medial prefrontal
cortex (measured by in vivo microdialysis) but enhance DA outflow in NA and STR
(Moghaddam and Bunney 1990).

Other researchers demonstrated that sulpiride (40

mg/kg) inhibits [3H]spiperone binding in several subcortical brain regions but not from
sites in frontal cortex (Jenner and Marsden, 1982; Kohler et al., 1979; Ogren et al., 1986)
or hippocampus (Jenner and Marsden, 1982).

Furthermore, 60 days' sulpiride

administration enhances the bromocriptine (D2 agonist)-induced inhibition of adenylate
cyclase in STR, but not in cortex or hippocampus (Memo et al., 1987).
Two trends in ChAT activity emerge from this research. The first trend indicates
that the ChAT response to endogenous DA following chronic DA receptor blockade is
related to the presence or absence of DAergic innervation. The regions that demonstrated
increased ChAT activity, that is, frontoparietal cortex, anterior cingulate, and amygdala,
receive significant mfb input.

The hippocampus is not a direct target of this fiber

pathway (Beckstead et al., 1979; Fallon and Moore, 1978; Palkovits and Brownstein,
1988) and demonstrated reduced ChAT levels. Thus, these results suggest that DA's
influence on ChAT in VP/SI neuron terminals may be the net effect of mfb influence on
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the cortex (i.e., mfb input to the cholinergic terminals themselves) and the VP/SI (i.e.,
input to cholinergic cell bodies). DA's influence on hippocampal ChAT may be limited
to mfb input to the septum.
The second trend involves the probable location of the cholinergic cell bodies
along the cholinergic column. The anterior cingulate and hippocampus, whose primary
cholinergic innervation originates in anterior portion of the column, selectively responded
to chronic treatment with sulpiride. Conversely, frontoparietal cortex receives terminals
from the posterior section and selectively responded to SCH 23390. Although projections
from cholinergic neurons along the entire length of the column reach the amygdala, it
only was sensitive to SCH 23390.

It is possible that this disparity is related to the

participation of the more posterior basal forebrain (including the SI) in the extended
amygdala system (Heimer and Alheid, 1990).
The results of this work also provide some insight to the functional status of the
cholinergic column.

Although cortex and hippocampus are innervated by different

sections of the column, "... a nuclear organization would predict that drugs that affect
[cholinergic parameters] in the hippocampus should have the same effect in the cortex"
(Schwaber et al., 1986). Conversely, if the MBN is composed of contiguous nuclei with
different afferent connections, cholinergic parameters "... would often be dissociable in the
different terminal projections of these nuclei" (Schwaber et al., 1986). The different
ChAT responses to chronic DA receptor antagonism indicate that the neurons forming the
basal forebrain cholinergic column are not a single functional unit. This agrees with some
earlier findings.

Robinson et al. (1978; 1979) observed that ACh turnover in
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hippocampus, but not cortex, is reduced after acute apomorphine (a dose sufficient to
induce stereotypy). Wood and Cheney (1978) reported that acute doses of antimuscarinic
drugs (i.e., benztropine, scopolamine, trihexyphenidyl) increase hippocampal and decrease
cortical ACh turnover rates.
The present data also demonstrate that chronic DA receptor antagonism does not
mimic the conditions in degenerative neural diseases. When ChAT activity is reduced in
human disease states such as Parkinson's disease (Ruberg et al., 1987) and Alzheimer's
disease (Gulya et al., 1986), the deficit occurs across the cortex and hippocampus. This
unidirectional change reflects cell loss, whereas the regional increases and decreases in
ChAT that occur after drug treatment demonstrate that the cholinergic cells are functional
but are subject to altered neurotransmitter influences.
The significance of the pattern of reactivity observed during this experiment needs
to be further explored. Understanding how neuroleptic drugs manipulate DAergic and
cholinergic function bears clinical relevance to the long term treatment of psychoses and
to resulting side effects such as tardive dyskinesia.
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